Study of SM-88 in Advanced Cancers

Breast Cancer Clinical Trial

Official title:

Ascending Multi-Dose Clinical Trial to Assess the Pharmacokinetics Efficacy of SM-88 Oral Administration in Breast Cancer Subjects

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02562612
• Other study ID #: SM-88-001
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: October 2022
• Est. completion date: October 2023

Study information

• Verified date: March 2021
• Source: Tyme, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to collect response and pharmacokinetic data on the oral administration of a cocktail combination of 4 drugs being developed for the indication of metastatic breast cancer.

Description:

The primary objective of this clinical trial is to assess the response rate and PFS in previously treated breast cancer patients. Additional objectives include the pharmacokinetics of multiple ascending doses of SM-88, a cocktail combination of 4 drugs being developed for the indication of metastatic breast cancer. Secondary objectives of this study include an assessment of safety and tolerability of ascending doses of orally administered SM-88. Additional response data will also be collected.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 2023
• Est. primary completion date: October 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Healthy adult subjects, between 18 and 70 years of age, that are willing and able to give written informed consent.

2. Subjects must be willing and able to comply with the clinical trial procedures and timelines as outlined in the Time and Events Table.

3. Subjects should be continuous nonsmokers and have not used nicotine-containing products for at least three months prior to dosing on Day 1.

4. Body mass index (BMI) between 20 and 29.

5. As outlined in section 5.1.1.1, subjects of childbearing potential must agree to use an approved method of contraception for the duration of the clinical trial and for three months after the dose of the IMP.

6. Must be able to swallow and retain oral medication.

7. Subjects must be willing to discontinue the use of any vitamins or herbal supplements seven days prior to the IMP dosing and not resume the use of these supplements until after PK sample is collected at 168h/Day 8.

Exclusion Criteria:

1. Prior medical history of any illness or injury that, in the opinion of the principal investigator (PI), that may confound the results of the clinical trial or pose an additional risk to the subject by his participation in the clinical trial.

2. Current or historic drug or alcohol abuse.

3. Unwillingness to discontinue alcohol intake for 24 hours prior to IMP dosing until the collection of the PK sample at 168-h/Day 8.

4. Subjects should not have a history of lactose intolerance.

5. Concurrent use or known history of hypersensitivity to any of the components of SM 88.

6. Clinically significant abnormal laboratory test results at screening and/or baseline visit as determined by PI.

7. Participation in another clinical trial within 30 days prior to screening.

8. Surgery within 90 days prior to dosing determined by the PI to be clinically relevant.

9. Subjects must be considered medically healthy with no clinically significant medical history.

10. Subjects cannot be taking any concomitant medications. Subjects must be willing to discontinue the use of any vitamins or herbal supplements seven days prior to the dose date of the clinical trial and remain off these supplements until the last PK sample is obtained (168h/Day 8).

11. Positive urine drug screening.

12. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• SM-88
Daily SM-88 in multiple ascending doses over 6 months

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tyme, Inc

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate	Response data will be collected on SM88 in breast cancer. SM88 has previously been reported to have clinical benefit in a variety of cancers (J Clin Oncol 31, 2013. suppl; abstr e22095)	6-12 months
Primary	PFS	PFS data will be collected on SM88 in breast cancer. SM88 has previously been reported to have clinical benefit in a variety of cancers (J Clin Oncol 31, 2013. suppl; abstr e22095)	6-12 months
Secondary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	The safety of orally administered SM-88 will be assessed by collected adverse events data as determined by physical exam, laboratory parameters and subject questionnaire.	30 days
Secondary	Blood concentration of SM-88	Blood sampling will be performed to establish the pharmacokinetic profile of SM-88. Time sampling will be at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5, 6, 8, 12, 48, and 168 hours post dose.	168 hours